Discovery of Potent o -Aminobenzoamide-Based NAMPT Inhibitors for Targeting NAPRT-Deficient Gastric Cancer
Journal of Medicinal Chemistry · 12.02.2026 · 69 (3) · 2625-2646
DOI: 10.1021/acs.jmedchem.5c02564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.01.2026. Verfasst von Heng Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Stomach Neoplasms, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China, Health Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD + salvage synthesis, represents an attractive target for gastric cancer therapy. Loss of nicotinic acid phosphoribosyltransferase (NAPRT) has been associated with an increased vulnerability to NAMPT inhibition in specific metabolic contexts. Here, we report the design and synthesis of o -aminobenzamide NAMPT inhibitors, among which compound N16 exhibited potent enzymatic selectivity and inhibition (IC 50 = 17.4 nM) and pronounced activity against NAPRT-deficient HGC-27 cells (IC 50 = 1.3 nM). N16 depleted NAD + and ATP, disrupted mitochondrial potential, and suppressed self-renewal, proliferation, invasion, and migration while inducing cell-cycle arrest and apoptosis. Compared with lead compound 1, N16 displayed improved pharmacokinetics and in vivo antitumor efficacy. Notably, nicotinic acid coadministration enhanced tolerability without compromising antitumor activity in vivo . Collectively, these findings identify N16 as a promising NAMPT inhibitor with translational potential for treating metabolically vulnerable gastric cancer, particularly NAPRT-deficient subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
- Postdoctoral Station for Basic Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
- School of Basic Medicine, The First Affiliated Hospital, The Second Affiliated Hospital, MOE Key Lab of Rare Pediatric Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
- Department of Oncology, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, China.
- Qinghai Provincial Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, Qinghai 810008, China.
- National Health Commission Key Laboratory of Birth Defect Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410008, China.
ORCID-Profile: Zhen Wang
Förderung
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
- Health Research Project of Hunan Provincial Health Commission
- Hunan Provincial Student Innovation and Entrepreneurship Training Program
- Science and Technology Plan Project of Hengyang City
- Postgraduate Scientific Research Innovation Project of Hunan Province
Zitieren
APA
Yang, H., Li, Z., Peng, H., Shen, L., Li, Z., Zhu, L., Ding, R., Shi, Y., Liu, Y., Zhang, M., Zhuo, L., Yang, M., Wang, Z., & Jiang, W. (2026). Discovery of Potent o -Aminobenzoamide-Based NAMPT Inhibitors for Targeting NAPRT-Deficient Gastric Cancer. Journal of Medicinal Chemistry, 69(3), 2625-2646. https://doi.org/10.1021/acs.jmedchem.5c02564
Vancouver
Yang H, Li Z, Peng H, Shen L, Li Z, Zhu L, et al. Discovery of Potent o -Aminobenzoamide-Based NAMPT Inhibitors for Targeting NAPRT-Deficient Gastric Cancer. Journal of Medicinal Chemistry. 2026;69(3):2625-2646. doi:10.1021/acs.jmedchem.5c02564
BibTeX
@article{Yang2026,
author = {Yang, Heng and Li, Zhiyi and Peng, Huiqian and Shen, Lixian and Li, Zhen and Zhu, Lejing and Ding, Rifan and Shi, Yiting and Liu, Yuting and Zhang, Miao and Zhuo, Linsheng and Yang, Meiling and Wang, Zhen and Jiang, Weifan},
title = {Discovery of Potent o -Aminobenzoamide-Based NAMPT Inhibitors for Targeting NAPRT-Deficient Gastric Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {3},
pages = {2625--2646},
doi = {10.1021/acs.jmedchem.5c02564}
}
EUVIMED